Eli Lilly CEO John Lechleiter has done the rounds in Asia with a recent stop in China an occasion for a chat about the company's plans in the Middle Kingdom with China Daily.
GlaxoSmithKline and Miltenyi Biotec have signed an R&D; cell and gene therapy pact that will see the British Big Pharma delve deeper into the brave new world of CAR-T-based oncology treatments. This brave new world will not however feature its leader, Andrew Witty, who announced his retirement today.
Valneva currently markets Ixiaro, a Japanese encephalitis vaccine and Dukoral, the cholera vaccine it acquired from Johnson & Johnson in 2015. Now, the Lyon, France-based vaccine maker is building on its relationship with the U.S. Department of Defense with a new $42 million supply contract for Ixiaro.
Osaka-based Takeda Pharmaceutical has exited a deal with Orexigen Therapeutics that sold back U.S. rights to obesity drug Contrave and at the same time announced a sharpened focus for its U.S. operations.
Roche is promising up to $1 billion in exchange for as many as 5 targeted cancer therapies from Blueprint Medicines, looking to bolster its own work in immuno-oncology.
Medical imaging deep learning startup Arterys has a major partnership with GE and a cardio product launch teed up as part of that for this fall. Now, it's lined up a more than $12 million Series A financing to help it transition into its next field: oncology. The San Francisco, CA-based startup had previously disclosed a smaller sum for that Series A of $7 million late last year.
Hyderabad-based Dr. Reddy's Laboratories has signed a deal with TR-Pharm to develop and manufacture three unspecified biosimilars, presumably from the India company's existing product and pipeline stable.
GlaxoSmithKline is cutting ties with Five Prime Therapeutics' in-development cancer therapy, backing out in the middle of a mesothelioma trial.
Icon has signed a deal with the International Consortium for Health Outcomes Measurement (ICHOM) to work out the best and cheapest ways of getting value-based healthcare to patients.
The Clinical Center at the National Institutes of Health (NIH) said last month that it would test a photon-counting CT scanner for the first time on humans. This is the first hospital-based research of this sort of device with more than 45 participants enrolled in the trial. The NIH noted that only three sites globally use this sort of technology.